Adenosine deaminase deficiency

Adenosine deaminase deficiency, or ADA deficiency, is an inherited immunodeficiency syndrome accounting for about 25% of all cases of severe combined immunodeficiency (SCID).

Additional recommended knowledge

Weighing the right way

Don't let static charges disrupt your weighing accuracy

Safe Weighing Range Ensures Accurate Results

This disease is due to a lack of the enzyme adenosine deaminase coded for by a gene on chromosome 20. There is an accumulation of dATP, which causes an increase in S-adenosylhomocysteine; both substances are toxic to immature lymphoid cells, so fail to reach maturity. As a result, the immune system of the afflicted person is severely compromised or completely lacking.

The enzyme adenosine deaminase is important for purine metabolism.

Treatment

Treatments include:

• bone marrow transplant
• gene therapy (efforts halted due to increased incidence of leukemia)
• ADA enzyme in PEG vehicle
• Stem Cell Therapy (still in the experimental stage)

On September 14, 1990, the first gene therapy to combat this disease was performed by Dr. W. French Anderson on a four year old girl, Ashanti DeSilva, at the National Institute of Health, Bethesda, Maryland, U.S.A.

The therapy performed was the first successful case of gene therapy.

External link

• Gene Therapy: A Brief History: [1]
• Gene Therapy Net